A capsid-modified helper-dependent adenovirus vector containing the β-globin locus control region displays a nonrandom integration pattern and allows stable, erythroid-specific gene expression

Journal of Virology

Volumn 79, Issue 17, 2005, Pages 10999-11013

  Wang, Hongjie ^a   Shayakhmetov, Dmitry M ^a   Leege, Tobias ^a,d   Harkey, Michael ^c   Li, Qiliang ^a   Papayannopoulou, Thalia ^b   Stamatoyannopolous, George ^a   Lieber, André ^a,b  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c Fred Hutchinson Cancer Research Center   (United States)

^d UNIVERSITY OF GREIFSWALD   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; BETA GLOBIN; GREEN FLUORESCENT PROTEIN;

ADENO ASSOCIATED VIRUS; ARTICLE; CHROMOSOME 11; CLONOGENESIS; CONTROLLED STUDY; ERYTHROID CELL; ERYTHROLEUKEMIA CELL; EXON; GENE EXPRESSION; GENE SILENCING; GENE TRANSFER; GENETIC TRANSDUCTION; HELPER CELL; HEMATOPOIETIC STEM CELL; HEMOGLOBINOPATHY; HUMAN; HUMAN CELL; INVERTED TERMINAL REPEAT; NONHUMAN; PRIORITY JOURNAL; REGULATOR GENE; UMBILICAL CORD BLOOD; VIRAL GENE THERAPY; VIRUS CAPSID; VIRUS DNA CELL DNA INTERACTION; X CHROMOSOME;

ADENOVIRIDAE; ANTIGENS, CD34; CAPSID; CELLS, CULTURED; GENE EXPRESSION; GENETIC VECTORS; GLOBINS; GREEN FLUORESCENT PROTEINS; HUMANS; LOCUS CONTROL REGION; TRANSDUCTION, GENETIC; VIRUS INTEGRATION;

ADENO-ASSOCIATED VIRUS; ADENOVIRIDAE; MIRIDAE;

EID: 23844541962     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.79.17.10999-11013.2005     Document Type: Article

References (62)

1. Avanzi, G. C., P. Lista, B. Giovinazzo, R. Miniero, G. Saglio, G. Benetton, R. Coda, G. Cattoretti, and L. Pegoraro. 1988. Selective growth response to IL-3 of a human leukaemic cell line with megakaryoblastic features. Br. J. Haematol. 69:359-366.
2. Barjot, C., D. Hartigan-O'Connor, G. Salvatori, J. M. Scott, and J. S. Chamberlain. 2002. Gutted adenoviral vector growth using E1/E2b/E3-deleted helper viruses. J. Gene Med. 4:480-489.
3. Boyer, J., K. Rohleder, and G. Ketner. 1999. Adenovirus E4 34k and E4 11k inhibit double strand break repair and are physically associated with the cellular DNA-dependent protein kinase. Virology 263:307-312.
4. Carlson, C. A., D. M. Shayakhmetov, and A. Lleber. 2002. Restoration of a functional open reading frame by homologous recombination between two adenoviral vectors. Mol. Ther. 6:99-105.
5. Carlson, C. A., D. S. Steinwaerder, H. Stecher, D. M. Shayakhmetov, and A. Lieber. 2002. Rearrangements in adenoviral genomes mediated by inverted repeats. Methods Enzymol. 346:277-292.
6. Carter, D., L. Chakalova, C. S. Osborne, Y. F. Dai, and P. Fraser. 2002. Long-range chromatin regulatory interactions in vivo. Nat. Genet. 32:623-626.
7. Chamberlain, J. S., C. Barjot, and J. Scott. 2003. Packaging cell lines for generating replication-defective and gutted adenoviral vectors. Methods Mol. Med. 76:153-166.
8. Ellis, J., and D. Pannell. 2001. The beta-globin locus control region versus gene therapy vectors: a struggle for expression. Clin. Genet. 59:17-24.
9. Gaggar, A., D. M. Shayakhmetov, and A. Lieber. 2003. CD46 is a cellular receptor for group B adenoviruses. Nat. Med. 9:1408-1412.
10. Goncalves, M. A., I. van der Velde, J. M. Janssen, B. T. Maassen, E. H. Heemskerk, D. J. Opstelten, S. Knaan-Shanzer, D. Valerio, and A. A. de Vries. 2002. Efficient generation and amplification of high-capacity adenoassociated virus/adenovirus hybrid vectors. J. Virol. 76:10734-10744.
11. Grosveld, F., E. de Boer, N. Dillon, P. Fraser, J. Gribnau, E. Milot, T. Trimborn, and M. Wijgerde. 1998. The dynamics of globin gene expression and gene therapy vectors. Semin. Hematol. 35:105-111.
12. Grosveld, F., G. B. van Assendelft, D. R. Greaves, and G. Kollias. 1987. Position-independent, high-level expression of the human beta-globin gene in transgenic mice. Cell 51:975-985.
13. Harui, A., S. Suzuki, S. Kochanek, and K. Mitani. 1999. Frequency and stability of chromosomal integration of adenovirus vectors. J. Virol. 73:6141-6146.
14. Hillgenberg, M., H. Tonnies, and M. Strauss. 2001. Chromosomal integration pattern of a helper-dependent minimal adenovirus vector with a selectable marker inserted into a 27.4-kilobase genomic stuffer. J. Virol. 75:9896-9908.
15. Karlsson, S., R. K. Humphries, Y. Gluzman, and A. W. Nienhuis. 1985. Transfer of genes into hematopoietic cells using recombinant DNA viruses. Proc. Natl. Acad. Sci. USA 82:158-162.
16. Karlsson, S., K. Van Doren, S. G. Schweiger, A. W. Nienhuis, and Y. Gluzman. 1986. Stable gene transfer and tissue-specific expression of a human globin gene using adenoviral vectors. EMBO J. 5:2377-2385.
17. Kochanek, S., G. Schiedner, and C. Volpers. 2001. High-capacity 'gutless' adenoviral vectors. Curr. Opin. Mol. Ther. 3:454-463.
18. Kohn, D. B., M. Sadelain, and J. C. Glorioso. 2003. Occurrence of leukaemia following gene therapy of X-linked SCID. Nat. Rev. Cancer 3:477-488.
19. Kubo, S., and K. Mitani. 2003. A new hybrid system capable of efficient lentiviral vector production and stable gene transfer mediated by a single helper-dependent adenoviral vector. J. Virol. 77:2964-2971.
20. Lanzov, V. A. 1999. Gene targeting for gene therapy: prospects. Mol. Genet. Metab. 68:276-282.
21. Leboulch, P., G. M. Huang, R. K. Humphries, Y. H. Oh, C. J. Eaves, D. Y. Tuan, and I. M. London. 1994. Mutagenesis of retroviral vectors transducing human beta-globin gene and beta-globin locus control region derivatives results in stable transmission of an active transcriptional structure. EMBO J. 13:3065-3076.
22. Li, Z., J. Dullmann, B. Schiedlmeier, M. Schmidt, C. von Kalle, J. Meyer, M. Forster, C. Stocking, A. Wahlers, O. Frank, W. Ostertag, K. Kuhlcke, H. G. Eckert, B. Fehse, and C. Baum. 2002. Murine leukemia induced by retroviral gene marking. Science 296:497.
23. Lieber, A., D. S. Steinwaerder, C. A. Carlson, and M. A. Kay. 1999. Integrating adenovirus-adeno-associated virus hybrid vectors devoid of all viral genes. J. Virol. 73:9314-9324.
24. Lieber, M. R., Y. Ma, U. Pannicke, and K. Schwarz. 2003. Mechanism and regulation of human non-homologous DNA end-joining. Nat Rev. Mol. Cell Biol. 4:712-720.
25. Marini, F. C., III, Q. Yu, T. Wickham, I. Kovesdi, and M. Andreeff. 2000. Adenovirus as a gene therapy vector for hematopoietic cells. Cancer Gene Ther. 7:816-825.
26. McCarty, D. M., S. M. Young, Jr., and R. J. Samulski. 2004. Integration of adeno-associated virus (AAV) and recombinant AAV vectors. Annu. Rev. Genet. 38:819-845.
27. Medin, J. A., and S. Karlsson. 1997. Viral vectors for gene therapy of hematopoietic cells. Immunotechnology 3:3-19.
28. Mitani, K., and S. Kubo. 2002. Adenovirus as an integrating vector. Curr. Gene Ther. 2:135-144.
29. Moore, M., and C. Ullman. 2003. Recent developments in the engineering of zinc finger proteins. Brief. Funct. Genomic. Proteomic. 1:342-355.
30. Murphy, S. J., H. Chong, S. Bell, R. M. Diaz, and R. G. Vile. 2002. Novel integrating adenoviral/retroviral hybrid vector for gene therapy. Hum. Gene Ther. 13:745-760.
31. Nahreini, P., S. H. Larsen, and A. Srivastava. 1992. Cloning and integration of DNA fragments in human cells via the inverted terminal repeats of the adeno-associated virus 2 genome. Gene 119:265-272.
32. Nakai, H., E. Montini, S. Fuess, T. A. Storm, L. Meuse, M. Finegold, M. Grompe, and M. A. Kay. 2003. Helper-independent and AAV-ITR-independent chromosomal integration of double-stranded linear DNA vectors in mice. Mol. Ther. 7:101-111.
33. Nilsson, M., S. Karlsson, and X. Fan. 2004. Functionally distinct subpopulations of cord blood CD34+ cells are transduced by adenoviral vectors with serotype 5 or 35 tropism. Mol. Ther. 9:377-388.
34. Olivares, E. C., R. P. Hollis, T. W. Chalberg, L. Meuse, M. A. Kay, and M. P. Calos. 2002. Site-specific genomic integration produces therapeutic Factor IX levels in mice. Nat. Biotechnol. 20:1124-1128.
35. Osborne, C. S., L. Chakalova, K. E. Brown, D. Carter, A. Horton, E. Debrand, B. Goyenechea, J. A. Mitchell, S. Lopes, W. Reik, and P. Fraser. 2004. Active genes dynamically colocalize to shared sites of ongoing transcription. Nat. Genet. 36:1065-1071.
36. Papayannopoulou, T., G. V. Priestley, A. Rohde, K. R. Peterson, and B. Nakamoto. 2000. Hemopoietic lineage commitment decisions: in vivo evidence from a transgenic mouse model harboring micro LCR-betapro-LacZ as a transgene. Blood 95:1274-1282.
37. Recchia, A., R. J. Parks, S. Lamartina, C. Toniatti, L. Pieroni, F. Palombo, G. Ciliberto, F. L. Graham, R. Cortese, N. La Monica, and S. Colloca. 1999. Site-specific integration mediated by a hybrid adenovirus/adeno-associated virus vector. Proc. Natl. Acad. Sci. USA 96:2615-2620.
38. Recchia, A., L. Perani, D. Sartori, C. Olgiati, and F. Mavilio. 2004. Site-specific integration of functional transgenes into the human genome by adeno/AAV hybrid vectors. Mol. Ther. 10:660-670.
39. Recchia, A., L. Perani, D. Sartori, and F. Mavilio. 2003. Site-specific integration in human somatic cell DNA by Adeno/AAV hybrid vectors. Mol. Ther. 7:S199.
40. Rivella, S., and M. Sadelain. 1998. Genetic treatment of severe hemoglobinopathies: the combat against transgene variegation and transgene silencing. Semin. Hematol. 35:112-125.
41. Romani, M., A. De Ambrosis, B. Alhadeff, M. Purrello, Y. Gluzman, and M. Siniscalco. 1990. Preferential integration of the Ad5/SV40 hybrid virus at the highly recombinogenic human chromosomal site 1p36. Gene 95:231-241.
42. Russell, D. W. 2003. AAV loves an active genome. Nat. Genet. 34:241-242.
43. Russell, D. W., I. E. Alexander, and A. D. Miller. 1995. DNA synthesis and topoisomerase inhibitors increase transduction by adeno-associated virus vectors. Proc. Natl. Acad. Sci. USA 92:5719-5723.
44. Sandig, V., R. Youil, A. J. Bett, L. L. Franlin, M. Oshima, D. Maione, F. Wang, M. L. Metzker, R. Savino, and C. T. Caskey. 2000. Optimization of the helper-dependent adenovirus system for production and potency in vivo. Proc. Natl. Acad. Sci. USA 97:1002-1007.
45. Schroder, A. R., P. Shinn, H. Chen, C. Berry, J. R. Ecker, and F. Bushman. 2002. HIV-1 integration in the human genome favors active genes and local hotspots. Cell 110:521-529.
46. Shayakhmetov, D. M., C. A. Carlson, H. Stecher, Q. Li, G. Stamatoyannopoulos, and A. Lieber. 2002. A high-capacity, capsid-modified hybrid adenovirus/adeno-associated virus vector for stable transduction of human hematopoietic cells. J. Virol. 76:1135-1143.
47. Shayakhmetov, D. M., Z. Y. Li, A. Gaggar, H. Gharwan, V. Ternovoi, V. Sandig, and A. Lieber. 2004. Genome size and structure determine efficiency of postinternalization steps and gene transfer of capsid-modified adenovirus vectors in a cell-type-specific manner. J. Virol. 78:10009-10022.
48. + cells by a retargeted adenovirus vector. J. Virol. 74:2567-2583.
49. Stamatoyannopoulos, J. A. 1992. Future prospects for treatment of hemoglobinopathies. West J. Med. 157:631-636.
50. Stamatoyannopoulos, J. A., C. H. Clegg, and Q. Li. 1997. Sheltering of gamma-globin expression from position effects requires both an upstream locus control region and a regulatory element 3′ to the A gamma-globin gene. Mol. Cell. Biol. 17:240-247.
51. Steinwaerder, D., and A. Lieber. 2000. Insulation from viral transcriptional regulatory elements improves inducible transgene expression from adenovirus vectors in vitro and in vivo. Gene Ther. 7:556-567.
52. Thomas, C. E., A. Ehrhardt, and M. A. Kay. 2003. Progress and problems with the use of viral vectors for gene therapy. Nat. Rev. Genet. 4:346-358.
53. Tisdale, J., and M. Sadelain. 2001. Toward gene therapy for disorders of globin synthesis. Semin. Hematol. 38:382-392.
54. Tolhuis, B., R. J. Palstra, E. Splinter, F. Grosveld, and W. de Laat. 2002. Looping and interaction between hypersensitive sites in the active beta-globin locus. Mol. Cell 10:1453-1465.
55. Urnov, F. D. 2003. Chromatin remodeling as a guide to transcriptional regulatory networks in mammals. J. Cell Biochem. 88:684-694.
56. Vijaya, S., D. L. Steffen, and H. L. Robinson. 1986. Acceptor sites for retroviral integrations map near DNase I-hypersensitive sites in chromatin. J. Virol. 60:683-692.
57. Xiao, X., W. Xiao, J. Li, and R. J. Samulski. 1997. A novel 165-base-pair terminal repeat sequence is the sole cis requirement for the adeno-associated virus life cycle. J. Virol. 71:941-948.
58. Yang, C. C., X. Xiao, X. Zhu, D. C. Ansardi, N. D. Epstein, M. R. Frey, A. G. Matera, and R. J. Samulski. 1997. Cellular recombination pathways and viral terminal repeat hairpin structures are sufficient for adeno-associated virus integration in vivo and in vitro. J. Virol. 71:9231-9247.
59. Yant, S. R., A. Ehrhardt, J. G. Mikkelsen, L. Meuse, T. Pham, and M. A. Kay. 2002. Transposition from a gutless adeno-transposon vector stabilizes transgene expression in vivo. Nat. Biotechnol. 20:999-1005.
60. Yotnda, P., H. Onishi, H. E. Heslop, D. Shayakhmetov, A. Lieber, M. Brenner, and A. Davis. 2001. Efficient infection of primitive hematopoietic stem cells by modified adenovirus. Gene Ther. 8:930-937.
61. Young, S. M., Jr., W. Xiao, and R. J. Samulski. 2000. Site-specific targeting of DNA plasmids to chromosome 19 using AAV cis and trans sequences. Methods Mol. Biol 133:111-126.
62. Zeng, M., G. J. Cerniglia, S. L. Eck, and C. W. Stevens. 1997. High-efficiency stable gene transfer of adenovirus into mammalian cells using ionizing radiation. Hum. Gene Ther. 8:1025-1032.